Skip to main content
Premium Trial:

Request an Annual Quote

Nastech Licenses RNAi Patents from Carnegie Institution

NEW YORK, Feb. 2 (GenomeWeb News) - Nastech Pharmaceutical Company has licensed RNA interference patents and patent applications from the Carnegie Institution of Washington, the company said today.


The worldwide, non-exclusive license covers small interfering RNA technology, including U.S. Patent 6,506,559 B1. Nastech plans to use the technology in tight junction research and to develop therapeutics.


Nastech, based in Bothell, Wash., is developing methods to deliver drugs through the nose.


The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.